Ganli Pharmaceutical: It is expected that the net profit in the first half of 2025 will increase by 100.73% - 114.12% year-on-year.

Ganli Pharmaceutical announced that it is expected to achieve a net profit attributable to the owners of the parent company of 6 billion to 6.4 billion yuan in the first half of 2025, an increase of 3.01 billion to 3.41 billion yuan compared to the same period of the previous year, a year-on-year increase of 100.73% to 114.12%. It is expected to achieve a net profit attributable to the owners of the parent company after deducting non-recurring gains and losses of 4.6 billion to 5 billion yuan in the first half of 2025, an increase of 3.33 billion to 3.73 billion yuan compared to the same period of the previous year, a year-on-year increase of 262.47% to 293.99%.